Prognostic significance of maximum standardized uptake value on 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in bone sarcomas
Cüneyt Tamam1, Müge Tamam2
1Department of Orthopedics and Traumatology, Specialist Private Practice, İstanbul, Turkey
2Department of Nuclear Medicine, University of Health Science, Okmeydanı Training and Research Hospital, İstanbul, Turkey
Keywords: Bone sarcoma; 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography; maximum standardized uptake value; survival.
Objectives: This study aims to evaluate the prognostic significance of maximum standardized uptake value (SUVmax) on 18F-fluoro-2-deoxyglucose positron emission tomography/ computed tomography (18FDG-PET/CT) for bone sarcoma.
Patients and methods: We retrospectively evaluated 34 patients (24 males, 10 females; mean age 36.6±24.2 years; range, 5 to 77 years) with pathologically proven bone sarcoma who underwent 18FDG-PET/CT for initial staging between September 2013 and September 2017. SUVmax of primary lesions were measured. Cumulative survival rate was calculated to evaluate the prognostic value of 18FDG-PET/CT findings. Survival duration was defined as the elapsed duration from the date of pre-treatment 18FDG-PET/CT scanning until the date of the final examination before the date of death.
Results: The cut-off value for SUVmax in the definition of progression was 8. Mean SUVmax of the progressive group was statistically significantly higher than the non-progressive group. Distant metastases were present in 14 (41.1%) cases. Mortality and cumulative survival rates were 14.7% and 79.1%±0.08%, respectively.
Conclusion: Semiquantitative estimation of primary tumor metabolic activity in terms of baseline SUVmax using 18FDG-PET/CT can predict the overall survival of patients with bone sarcoma.